791 related articles for article (PubMed ID: 7562556)
1. Interactions of dopaminergic and GABAergic neurotransmission: impact of 6-hydroxydopamine lesions into the substantia nigra of rats.
Hossain MA; Weiner N
J Pharmacol Exp Ther; 1995 Oct; 275(1):237-44. PubMed ID: 7562556
[TBL] [Abstract][Full Text] [Related]
2. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Hossain MA; Weiner N
J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
[TBL] [Abstract][Full Text] [Related]
3. CGP 56999A, a GABA(B) receptor antagonist, enhances expression of brain-derived neurotrophic factor and attenuates dopamine depletion in the rat corpus striatum following a 6-hydroxydopamine lesion of the nigrostriatal pathway.
Enna SJ; Reisman SA; Stanford JA
Neurosci Lett; 2006 Oct; 406(1-2):102-6. PubMed ID: 16890350
[TBL] [Abstract][Full Text] [Related]
4. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
Wachtel SR; Hu XT; Galloway MP; White FJ
Synapse; 1989; 4(4):327-46. PubMed ID: 2532422
[TBL] [Abstract][Full Text] [Related]
5. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
Sonsalla PK; Manzino L; Heikkila RE
J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
[TBL] [Abstract][Full Text] [Related]
6. Interhemispheric modulation of dopamine receptor interactions in unilateral 6-OHDA rodent model.
Lawler CP; Gilmore JH; Watts VJ; Walker QD; Southerland SB; Cook LL; Mathis CA; Mailman RB
Synapse; 1995 Dec; 21(4):299-311. PubMed ID: 8869160
[TBL] [Abstract][Full Text] [Related]
7. Substantia nigra glutamate antagonists produce contralateral turning and basal ganglia Fos expression: interactions with D1 and D2 dopamine receptor agonists.
McPherson RJ; Marshall JF
Synapse; 2000 Jun; 36(3):194-204. PubMed ID: 10819899
[TBL] [Abstract][Full Text] [Related]
8. Interactions between dopamine D1 receptors and gamma-aminobutyric acid mechanisms in substantia nigra pars reticulata of the rat: neurochemical and behavioral studies.
Trevitt T; Carlson B; Correa M; Keene A; Morales M; Salamone JD
Psychopharmacology (Berl); 2002 Jan; 159(3):229-37. PubMed ID: 11862355
[TBL] [Abstract][Full Text] [Related]
9. GABA(B) receptor activation inhibits dopamine D1 receptor-mediated facilitation of [(3)H]GABA release in substantia nigra pars reticulata.
Nava-Asbell C; Paz-Bermudez F; Erlij D; Aceves J; Florán B
Neuropharmacology; 2007 Oct; 53(5):631-7. PubMed ID: 17868750
[TBL] [Abstract][Full Text] [Related]
10. Alterations in nigral NMDA and GABAA receptor control of the striatal dopamine level after repetitive exposures to nitrogen narcosis.
Lavoute C; Weiss M; Rostain JC
Exp Neurol; 2008 Jul; 212(1):63-70. PubMed ID: 18452916
[TBL] [Abstract][Full Text] [Related]
11. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
Löschmann PA; Wüllner U; Heneka MT; Schulz JB; Kunow M; Wachtel H; Klockgether T
Synapse; 1997 Aug; 26(4):381-91. PubMed ID: 9215597
[TBL] [Abstract][Full Text] [Related]
12. Modulation of GABA release by dopamine in the substantia nigra.
Matuszewich L; Yamamoto BK
Synapse; 1999 Apr; 32(1):29-36. PubMed ID: 10188635
[TBL] [Abstract][Full Text] [Related]
13. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease.
Calabresi P; Mercuri NB; Sancesario G; Bernardi G
Brain; 1993 Apr; 116 ( Pt 2)():433-52. PubMed ID: 8096420
[TBL] [Abstract][Full Text] [Related]
14. Dopamine control of seizure propagation: intranigral dopamine D1 agonist SKF-38393 enhances susceptibility to seizures.
Turski WA; Cavalheiro EA; Ikonomidou C; Bortolotto ZA; Klockgether T; Turski L
Synapse; 1990; 5(2):113-9. PubMed ID: 2137942
[TBL] [Abstract][Full Text] [Related]
15. Substantia nigra 6-hydroxydopamine lesions alter dopaminergic synaptic markers in the nucleus basalis magnocellularis and striatum of rats.
Geula C; Slevin JT
Synapse; 1989; 4(3):248-53. PubMed ID: 2532792
[TBL] [Abstract][Full Text] [Related]
16. [Interactions of GABAergic and catecholaminergic neurotransmissions. Effects of dopaminergic and noradrenergic agonists and antagonists on GABA turnover].
Bernasconi R; Steulet AF; Aryee D; Martin P; Leonhardt T; Bischoff S; Maitre L
Encephale; 1989; 15(4):377-85. PubMed ID: 2572414
[TBL] [Abstract][Full Text] [Related]
17. Effects of NMDA and MK-801 injected into the substantia nigra pars reticulata on jaw movements evoked by dopamine D1-/D2 receptor stimulation in the ventrolateral striatum: studies in freely moving rats.
Uchida T; Lee J; Fujita S; Kiguchi M; Matsumoto M; Oi Y; Gionhaku N; Koshikawa N
Methods Find Exp Clin Pharmacol; 2005; 27(1):31-7. PubMed ID: 15834457
[TBL] [Abstract][Full Text] [Related]
18. Electrophysiological effects of SKF 38393 in rats with reserpine treatment and 6-hydroxydopamine-induced nigrostriatal lesions reveal two types of plasticity in D1 dopamine receptor modulation of basal ganglia output.
Huang KX; Walters JR
J Pharmacol Exp Ther; 1994 Dec; 271(3):1434-43. PubMed ID: 7996456
[TBL] [Abstract][Full Text] [Related]
19. Nigrostriatal lesion and dopamine agonists affect firing patterns of rodent entopeduncular nucleus neurons.
Ruskin DN; Bergstrom DA; Walters JR
J Neurophysiol; 2002 Jul; 88(1):487-96. PubMed ID: 12091570
[TBL] [Abstract][Full Text] [Related]
20. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
Hu XT; White FJ
Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
